AzTrials
AzTrials

StrokeEspertaMenteNCT07504692

Biodiversity and Human Functioning Following Acquired Cerebrovascular Lesions - Phase 1

An observational study of Stroke, run by Dr. Franco Molteni at 3 sites in Italy.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The study aims to investigate the impact that the set of factors to which a post-stroke person is exposed during daily life can have on their health. The study will examine the totality of conditions, known as the "exposome," which include biological, environmental, social, and lifestyle factors. Read more about this study

Who is it for?
Ages 5 years and older
Conditions the study is for
Stroke
How many people
150 participants
Where
3 sitesItaly
Study dates
26 Mar 2025to 30 Nov 2025
How long will I take part?
1 Day
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 5 years and older
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: post-stroke patients

Who may be able to join

  • Subjects with Cerebral Stroke, both ischemic and hemorrhagic, in either pediatric or adult age;
  • Age > 5 years
  • Absence of ongoing clinical acute conditions
  • Able to provide written informed consent to participate in the study if of legal age, or consent from a legal representative if a minor
  • Absence of major psychiatric disorders associated with the disability condition

Who cannot join

  • Inability to provide informed consent
  • Presence of other neurological conditions (e.g. Multiple Sclerosis, Parkinson's Disease…)
  • Presence of ongoing clinical acute conditions
  • Presence of major psychiatric disorders associated with the disability condition

Trial locations and contacts

3 sites in 1 country.

Italy3 sites
  • IRCCS Scientific Institute E. Medea

    Bosisio Parini, Lecco, 23842

  • Villa Beretta Rehabilitation Center

    Costa Masnaga, Lecco, 23845

  • IRCCS Fondazione Don Carlo Gnocchi

    Milan, Milano, 20148

Other trials in Italy

About this study

Official title: Esposoma: Biodiversità e Human Functioning Post Lesioni Vascolari Cerebrali Acquisite

The study aims to investigate the impact that the set of factors to which a post-stroke person is exposed during daily life can have on their health. The study will examine the totality of conditions, known as the "exposome," which include biological, environmental, social, and lifestyle factors.

Read the detailed description

The exposome represents the complex set of environmental conditions to which an individual is exposed throughout their entire life, including factors such as light, atmospheric pollutants, diet, lifestyles, stress, and interpersonal relationships that are closely correlated with the environmental context and the social network in which and with which the person lives (e.g., rural/metropolitan context, presence or absence of a caregiver) (D'Errico et al., 2023).

The WHO evaluates health in bio-psycho-social terms to arrive at the concept of human functioning and "lived health" (Bickenbach et al., 2023), meaning the ability to carry out daily activities and social participation with the best possible personal and environmental interaction. Studies correlating the exposome with human functioning outcomes in post-stroke patients are extremely limited to date. Indeed, most clinical scales assess the motor, cognitive, and relational abilities of the individual and their impact on quality of life, but the socio-environmental interactions of the individual (e.g., sociodemographic, psychological factors, and living environment) are not systematically included in the analysis (Fahey et al., 2018).

Among the elements of the exposome to be considered, the dual patient-caregiver relationship plays an absolutely central role, as does the environmental context in which patient and caregiver express relationships and activities through which they give form and meaning to emotions, intentions, and resulting actions that shape behaviors and lifestyles.

For all these reasons, it is necessary to redefine multifactorial outcome measures that quantify and qualify relevant aspects of the exposome in an integrated way.

Urbanization and the varying geographical context of residence also carry significant weight in the exposome. "Rural" settings generally allow for greater experience of biodiversity with natural environments and greater exposure to natural light, positively influencing circadian rhythms with antidepressant effects potentially comparable to pharmacological treatments (Burgess et al., 2010). Equally important are contexts that facilitate social relationships, with the potential to significantly and positively influence the psychological well-being of individuals and their perceived sense of happiness (Beccetti et al., 2023). "Metropolitan" contexts, on the other hand, are characterized by environmental situations that may include sources of light pollution, which is associated with a higher risk of psychiatric disorders (Nature 2023, editorial), reduced air quality - associated with obesity and metabolic problems in children (Maitre et al., 2022) - as well as other environmental constraints such as architectural barriers and a fragmented human relational fabric that lead to restrictions or impoverishment of social participation.

Unfavorable environmental conditions can also negatively influence mechanisms of inflammation and systemic immunity (Vieujean S., 2022). Numerous data show that inflammation affects the nervous system both indirectly and through the disruption of slow-wave sleep phases (Gerhard et al., 2000; Block et al., 2005), with consequent alterations in brain plasticity (Facchin et al., 2020) and functional recovery. The combined analysis of inflammation and EEG in post-stroke patients can provide fundamental data for better understanding the role played by the environment in the reconfiguration of functional networks. In particular, inflammasomes, the Natural Killer immune response, cortisol, melatonin, and catecholamine concentrations, neurotrophic factors in peripheral extracellular vesicles of astrocytic origin (ADEVs), single nucleotide polymorphisms (SNPs), and microRNAs can provide information individually or in combination with EEG-based slow-wave sleep detection.

These findings suggest that the exposome and biodiversity may have a determining impact through components that can influence human functioning, with evident potential consequences for the lived health conditions of post-stroke individuals and their caregivers. Biodiversity, which can also be expressed through varied multisensory stimulation, can induce changes in the lifestyle of the individual and their immediate social network, consequently modifying human functioning and creating the bio-psycho-social conditions essential for maintaining and enhancing the results achieved through rehabilitation processes in stroke patients.

In particular, correlations between exposure to both natural and artificial light and modifications in neurophysiological, functional, and biological responses - investigated in numerous studies - suggest its prominent role in both the internal and external exposome (McGlashan et al., 2021; Sabbah et al., 2022).

The limitations of existing studies and the limited exploration of the impact the exposome may have on rehabilitation outcomes in post-stroke patients define an important scientific context to be systematically explored, in order to create new models for evaluating the health status derived from integrated multimodal rehabilitation processes. The challenges that future research will need to address are: i) the adoption of an interdisciplinary approach; ii) the introduction of multifactorial bio-psycho-social analyses; iii) the study of heterogeneous patient populations across the lifespan, with specific reference to developmental age; iv) the inclusion, recognition, and analysis of the role and lived experience of caregivers.

Conditions
Stroke
Keywords
Caregiver, Human Functioning, Environment, Biomarkers, Exposome
Medical subject headings
Stroke

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT07504692
Study groupRoleWhat they receive
Post stroke patients in chronic conditionThe study will include patients with post-stroke outcomes and their caregivers. Patients with ischemic or hemorrhagic stroke outcomes will be included, divided into age groups: a) 30 pediatric stroke patients (age < 18 years at the time of the acute event) ; b) 120 stroke patients (60 patients aged ≤ 65 years at the time of the acute event, 60 patients aged > 65 years at the time of the acute event). Of these, 40 patients will be 10 years post acute event, 40 patients will be 5 years post acute event, and 40 will be recruited from patients hospitalized for a recent stroke event. The selected population will be representative of the general population of patients with post-stroke disabilities, reflecting their biodiversity in terms of sex, age, ethnicity, educational level, socioeconomic conditions, and level of motor and cognitive impairment.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Motor measures

    10 metres walking test: 10mWT (lower values better performance)

    Measured: Baseline

  2. Motor measure

    6 minutes walking test: 6mWT (higher values better performance)

    Measured: Baseline

  3. Motor Measure

    Timed Up and Go test: TUG (lower values better performance)

    Measured: Baseline

  4. Motor measure

    Berg balance scale: BBS (0-56 higher values better performance)

    Measured: Baseline

  5. motor outcome measure

    Functional Ambulation Category: FAC (0-5 higher values better performance)

    Measured: Baseline

  6. Cognitive measure

    MoCa Test: MOCA (0-30 higher values better performance)

    Measured: Baseline

Secondary outcomes (9)
  1. Biomarkers from blood samples

    cortisol

    Measured: Baseline

  2. Biomarkers from blood samples

    melatonin

    Measured: Baseline

  3. Biomarkers from blood samples

    catecholamines

    Measured: Baseline

  4. Biomakers from blood samples

    genetic polymorphisms

    Measured: baseline

  5. Biomarkers from blood samples

    inflammatory cytokines

    Measured: Baseline

  6. Patients' reported outcome

    WHODAS (0-100 higher values worse disability)

    Measured: Baseline

  7. Patient's reported outcome

    Stroke Impact Scale: SIS (0-100 higher values better condition)

    Measured: Baseline

  8. Patient's reported outcome

    Fatigue Impact Scale: FIS (0-160 lower values better condition)

    Measured: Baseline

  9. Patient's reported outcome

    Pittsburgh Scale: PSQI (0-21 lower values better sleep quality)

    Measured: Baseline

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Apr 2026
  2. Study start26 Mar 2025
  3. Primary completion30 Sep 2025
  4. Study completion30 Nov 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case only
Time perspective
Cross-sectional
Enrolment
150 participants (actual)
Target duration
1 Day
IDs, dates and publications
ClinicalTrials.gov ID
NCT07504692
Sponsor's protocol ID
Espertamente Fase1
Acronym
EspertaMente
Status last verified
Mar 2026
First submitted
5 Mar 2026
Last updated
14 Aug 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Stroke, run by Dr. Franco Molteni at 3 sites in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 14 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 3 sites in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Motor measures (time frame: Baseline). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Aug 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in